Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Planet MicroCap Logo on Vegas Background

Share This Post

NEW YORK, June 4, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.

Conference Details

Date: June 16-18, 2026

Location: Bellagio Hotel & Casino, Las Vegas

Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT

Presentation Location: Track 7 – Donatello 3

Registration: Interested investors can register to attend here

Webcast: Viewable here

Booth: 413

The Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedule a meeting with the INBS management team, please contact your Planet MicroCap representative or email KCSA Strategic Communications at INBS@kcsa.com.

 

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/ 

Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

 

INBS Reports Record Fiscal Q1 2027 Revenue of $1.39M

Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth

NEW YORK, November 10, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2026. “Fiscal first quarter revenue was the highest quarterly revenue in our Company’s…

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

NEW YORK, September 09, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA),  seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the “System”)…

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.